125 related articles for article (PubMed ID: 27154286)
1. The solvent at antigen-binding site regulated C3d-CR2 interactions through the C-terminal tail of C3d at different ion strengths: insights from molecular dynamics simulation.
Zhang Y; Guo J; Li L; Liu X; Yao X; Liu H
Biochim Biophys Acta; 2016 Oct; 1860(10):2220-31. PubMed ID: 27154286
[TBL] [Abstract][Full Text] [Related]
2. The molecular mechanism of pH-regulating C3d-CR2 interactions: Insights from molecular dynamics simulation.
Zhang Y; Guo J; Ning L; Tian J; Yao X; Liu H
Chem Biol Drug Des; 2019 Apr; 93(4):628-637. PubMed ID: 30566277
[TBL] [Abstract][Full Text] [Related]
3. Immunophysical exploration of C3d-CR2(CCP1-2) interaction using molecular dynamics and electrostatics.
Zhang L; Mallik B; Morikis D
J Mol Biol; 2007 Jun; 369(2):567-83. PubMed ID: 17434528
[TBL] [Abstract][Full Text] [Related]
4. Molecular dynamics simulations of wild type and mutants of human complement receptor 2 complexed with C3d.
Wan H; Hu JP; Tian XH; Chang S
Phys Chem Chem Phys; 2013 Jan; 15(4):1241-51. PubMed ID: 23229122
[TBL] [Abstract][Full Text] [Related]
5. A theoretical view of the C3d:CR2 binding controversy.
Mohan RR; Gorham RD; Morikis D
Mol Immunol; 2015 Mar; 64(1):112-22. PubMed ID: 25433434
[TBL] [Abstract][Full Text] [Related]
6. Structure-guided identification of C3d residues essential for its binding to complement receptor 2 (CD21).
Clemenza L; Isenman DE
J Immunol; 2000 Oct; 165(7):3839-48. PubMed ID: 11034390
[TBL] [Abstract][Full Text] [Related]
7. Electrostatic Steering Accelerates C3d:CR2 Association.
Mohan RR; Huber GA; Morikis D
J Phys Chem B; 2016 Aug; 120(33):8416-23. PubMed ID: 27092816
[TBL] [Abstract][Full Text] [Related]
8. The electrostatic nature of C3d-complement receptor 2 association.
Morikis D; Lambris JD
J Immunol; 2004 Jun; 172(12):7537-47. PubMed ID: 15187133
[TBL] [Abstract][Full Text] [Related]
9. Delineation of the complement receptor type 2-C3d complex by site-directed mutagenesis and molecular docking.
Shaw CD; Storek MJ; Young KA; Kovacs JM; Thurman JM; Holers VM; Hannan JP
J Mol Biol; 2010 Dec; 404(4):697-710. PubMed ID: 20951140
[TBL] [Abstract][Full Text] [Related]
10. Mutational analysis of the complement receptor type 2 (CR2/CD21)-C3d interaction reveals a putative charged SCR1 binding site for C3d.
Hannan JP; Young KA; Guthridge JM; Asokan R; Szakonyi G; Chen XS; Holers VM
J Mol Biol; 2005 Feb; 346(3):845-58. PubMed ID: 15713467
[TBL] [Abstract][Full Text] [Related]
11. Structural studies in solution of the recombinant N-terminal pair of short consensus/complement repeat domains of complement receptor type 2 (CR2/CD21) and interactions with its ligand C3dg.
Guthridge JM; Rakstang JK; Young KA; Hinshelwood J; Aslam M; Robertson A; Gipson MG; Sarrias MR; Moore WT; Meagher M; Karp D; Lambris JD; Perkins SJ; Holers VM
Biochemistry; 2001 May; 40(20):5931-41. PubMed ID: 11352728
[TBL] [Abstract][Full Text] [Related]
12. A minimum CR2 binding domain of C3d enhances immunity following vaccination.
Bower JF; Ross TM
Adv Exp Med Biol; 2006; 586():249-64. PubMed ID: 16893077
[TBL] [Abstract][Full Text] [Related]
13. Epitope mapping using the X-ray crystallographic structure of complement receptor type 2 (CR2)/CD21: identification of a highly inhibitory monoclonal antibody that directly recognizes the CR2-C3d interface.
Guthridge JM; Young K; Gipson MG; Sarrias MR; Szakonyi G; Chen XS; Malaspina A; Donoghue E; James JA; Lambris JD; Moir SA; Perkins SJ; Holers VM
J Immunol; 2001 Nov; 167(10):5758-66. PubMed ID: 11698449
[TBL] [Abstract][Full Text] [Related]
14. Mutational analyses reveal that the staphylococcal immune evasion molecule Sbi and complement receptor 2 (CR2) share overlapping contact residues on C3d: implications for the controversy regarding the CR2/C3d cocrystal structure.
Isenman DE; Leung E; Mackay JD; Bagby S; van den Elsen JM
J Immunol; 2010 Feb; 184(4):1946-55. PubMed ID: 20083651
[TBL] [Abstract][Full Text] [Related]
15. A complement C3 fragment equivalent to mammalian C3d from the common carp (Cyprinus carpio): generation in serum after activation of the alternative pathway and detection of its receptor on the lymphocyte surface.
Nakao M; Miura C; Itoh S; Nakahara M; Okumura K; Mutsuro J; Yano T
Fish Shellfish Immunol; 2004 Feb; 16(2):139-49. PubMed ID: 15123318
[TBL] [Abstract][Full Text] [Related]
16. The Structure-Function Relationships of Complement Receptor Type 2 (CR2; CD21).
Hannan JP
Curr Protein Pept Sci; 2016; 17(5):463-87. PubMed ID: 26916158
[TBL] [Abstract][Full Text] [Related]
17. Evidence for multiple sites of interaction in C3 for complement receptor type 2 (C3d/EBV receptor, CD21).
Esparza I; Becherer JD; Alsenz J; De la Hera A; Lao Z; Tsoukas CD; Lambris JD
Eur J Immunol; 1991 Nov; 21(11):2829-38. PubMed ID: 1834472
[TBL] [Abstract][Full Text] [Related]
18. Complement-mediated activation of the adaptive immune responses: role of C3d in linking the innate and adaptive immunity.
Toapanta FR; Ross TM
Immunol Res; 2006; 36(1-3):197-210. PubMed ID: 17337780
[TBL] [Abstract][Full Text] [Related]
19. Solution structure of the complex between CR2 SCR 1-2 and C3d of human complement: an X-ray scattering and sedimentation modelling study.
Gilbert HE; Eaton JT; Hannan JP; Holers VM; Perkins SJ
J Mol Biol; 2005 Feb; 346(3):859-73. PubMed ID: 15713468
[TBL] [Abstract][Full Text] [Related]
20. Mapping of the C3d receptor (CR2)-binding site and a neoantigenic site in the C3d domain of the third component of complement.
Lambris JD; Ganu VS; Hirani S; Müller-Eberhard HJ
Proc Natl Acad Sci U S A; 1985 Jun; 82(12):4235-9. PubMed ID: 2408276
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
